Tilray Brands shows an extreme risk/reward skew with 117% analyst upside and a passed asymmetry gate, but quality below the engine's floor, a confirmed downtrend with a death-cross block, and high short interest keep the engine's recommendation at exit.
Thesis pillars
- Quality Below Floor Value Trap↑Improving
- High Asymmetry Large Analyst Upside→Stable
- Failed Momentum Confirmed Downtrend→Stable
- +1 more pillar — see the Why tab for full reasoning
Tilray Brands, Inc. (TLRY) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $3.36: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Tilray Brands is a cannabis, beverage and wellness company selling adult-use and medical cannabis products in Canada and internationally, alongside other consumer brands. Its Canadian adult-use business is shaped by federal and provincial marketing and product restrictions.
Sell if holding. Engine safety override at $3.36: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 19, MACD bearish. Score 5.8/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Tilray Brands, Inc.
About Tilray Brands, Inc.
Tilray Brands generated $821.3 million in total net revenue for the fiscal year ended May 31, 2025, spread across four segments: Distribution (33%), Cannabis (30%), Beverage (29%), and Wellness (8%). Within the Cannabis segment, Canadian adult-use cannabis sales accounted for 91% of segment revenue, with the remainder split between Canadian medical cannabis, wholesale, and international cannabis sales. The company markets over a dozen beverage, cannabis, and wellness brands, including SweetWater Brewing and Manitoba Harvest.
Tilray earns revenue from four distinct business lines: Beverage (production, marketing, and sale of craft beer and spirits under brands including SweetWater Brewing, Breckenridge Brewery, and Atwater), Cannabis (cultivation, production, distribution, and sale of medical and adult-use cannabis, primarily in Canada), Distribution (purchase, resale, and distribution of third-party pharmaceutical and wellness products, mainly through its German subsidiary CC Pharma), and Wellness (production and marketing of hemp-based foods under the Manitoba Harvest and Humble Seed brands). The company expanded its U.S. beverage platform through two acquisitions of craft brewing brands — Craft Acquisition I from Anheuser-Busch in September 2023 and Craft Acquisition II from Molson Coors in September 2024 — a diversification strategy management frames explicitly as a way to access the U.S. market ahead of, or independent from, federal cannabis legalization. International medical cannabis is supplied to patients in over 20 countries through EU-GMP production facilities in Portugal and Germany.
Show full overview
Tilray's cannabis business remains structurally exposed to a single regulatory threshold that has not yet been crossed: the 10-K states that in the event recent efforts to reschedule cannabis as a Schedule III substance in the U.S. prevail and enable Tilray to enter the medical cannabis business, the company believes its existing leadership position in Canada, Europe, and Australia would let it launch U.S. medical cannabis operations quickly. Until that rescheduling or federal legalization occurs, Tilray's U.S. cannabis-market access is confined to its beverage, wellness, and distribution businesses rather than cannabis itself — meaning the timing of a single U.S. federal policy decision, not a competitive or operational factor, is what would unlock the segment where Tilray already claims category leadership in Canada.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Tilray Brands, Inc.'s most recent 10-K filing, extracted August 9, 2026.
Recent developments
updated 2026-10-13Recent Developments — Tilray Brands, Inc.
Latest news
- NEWS Tilray Brands’ Unit Tilray Medical Secures Key Regulatory Approval For In-House Testing At Portugal Facility — benzinga Oct 13, 2026 positive
- NEWS Canaccord Genuity Maintains Hold on Tilray Brands, Lowers Price Target to $4 — benzinga Oct 9, 2026 negative
- NEWS Tilray Brands Q1 2027 Earnings Call Transcript — benzinga Oct 8, 2026 neutral
- NEWS Earnings Scheduled For October 8, 2026 — benzinga Oct 8, 2026 neutral
- NEWS Tilray Brands Q1 Adj. EPS $(0.02) Beats $(0.20) Estimate, Sales $257.147M Miss $267.813M Estimate — benzinga Oct 8, 2026 negative
Generated 2026-10-13T11:37:17Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -17.1%. Quality floor flags this regardless of sector context.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.36: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 6.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 19, MACD bearish. Prior stop was $3.24. Score 5.8/10, moderate confidence.
Take-profit target: $5.61 (+66.9% upside). Prior stop was $3.24. Stop-loss: $3.24.
Quality below floor (2.2 < 4.0).
Tilray Brands, Inc. trades at a P/E of N/A (forward 20.1). TrendMatrix value score: 7.1/10. Verdict: Sell.
17 analysts cover TLRY with a consensus score of 3.6/5. Average price target: $6.
What does Tilray Brands, Inc. do?Tilray Brands is a cannabis, beverage and wellness company selling adult-use and medical cannabis products in Canada...
Tilray Brands is a cannabis, beverage and wellness company selling adult-use and medical cannabis products in Canada and internationally, alongside other consumer brands. Its Canadian adult-use business is shaped by federal and provincial marketing and product restrictions.